Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune system dysregulation.
• MicroRNAs (miRNAs) play crucial roles in regulating immune cell function and are implicated in autoimmune diseases.
• The specific role of miR-7 in the pathogenesis of SLE remains incompletely understood.

Purpose of the Study:

• To investigate the biological function of miR-7 in a mouse model of systemic lupus erythematosus (SLE).
• To determine the therapeutic potential of targeting miR-7 in SLE.
• To elucidate the molecular mechanisms by which miR-7 influences immune cell activity in lupus.

Main Methods:

• Administration of antagomiR-7 or a control to MRL^lpr/lpr lupus mice.
• Assessment of lupus manifestations using immunofluorescence, immunohistochemistry, and autoantibody/cytokine profiling.
• Flow cytometry analysis of splenic B cell subsets and T follicular helper (Tfh) cell expansion, including PI3K/AKT and STAT3 signaling pathways.

Main Results:

• miR-7 was found to be upregulated in MRL^lpr/lpr lupus mice and directly targets PTEN mRNA in B cells.
• AntagomiR-7 treatment significantly reduced lupus manifestations, normalized splenic B cell subtypes, and decreased Tfh cell expansion.
• miR-7 inhibition downregulated PTEN/AKT signaling, suppressed B cell differentiation and germinal center formation, and reduced IL-21 production.

Conclusions:

• miR-7 plays a critical role in regulating PTEN expression and the function of B cells and Tfh cells in lupus-prone mice.
• AntagomiR-7 effectively ameliorated disease manifestations in MRL^lpr/lpr lupus mice.
• Targeting miR-7 represents a promising therapeutic strategy for systemic lupus erythematosus (SLE).